Currently, NB patients are stratified into low-, intermediate-, or high-risk categories based on a risk assessment of well-defined prognostic factors including the age at diagnosis, International Neuroblastoma Staging System (INSS) stage, tumor histopathology, MYCN amplification status and tumor DNA ploidy. The gene discussed is MYCN; the disease is neuroblastoma.